

Promising Results for mRNA & Small Molecule Immunotherapies to Defeat Cancer & Autoimmune Disorders: New Interview \$RGBP

Word Spreading on Promising Results for mRNA and Small Molecule Immunotherapies to Defeat Cancer and Serious Autoimmune Disorders: Regen BioPharma

LA MESA, CALIFORNIA, UNITED STATES , November 7, 2023 /EINPresswire.com/ -- Word Spreading on Promising Results for mRNA and Small Molecule Immunotherapies to Defeat Cancer and Serious Autoimmune Disorders: Regen BioPharma ([Stock Symbol: RGBP](#))

For more information on \$RGBP visit: <http://www.regenbiopharmainc.com>

Watch the RGBP Video here: <https://www.youtube.com/watch?v=7LhOazAjmvU>




Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity”
Dr. David Koos, Chairman and CEO of RGBP

Advancing Therapies for Treating Cancer and Autoimmune Disorders by Modulating the Immune Checkpoint NR2F6.

Applying a Genetic Approach to Regulating NR2F6 Levels in Human T Cells.

Additional Work for Blood Disorders, Cellular Immunotherapy, Modulating Key Molecular Processes in Cancer Stem Cell and Repairing Damaged Bone Marrow.



New Presentation of RGBP DuraCAR Program and Current Company Financing at the Emerging Growth Conference Held on November 1, 2023.

Received Unexpected and Potentially Extremely Useful Data on Experimental Studies on the Company's DuraCAR CAR T-Cell Therapeutic.



Second Phase Confirmatory Data Received on DuraCAR CAR-T Cell Therapy Program; Autoimmunity to be Targeted.

Studies Demonstrated That T Cells Which Express the Chimeric Antigen Receptor (CAR) Construct Expressing siRNA for NR2F6 can be Successfully Created.

Second Unrelated qRT-PCR Testing Underway to Determine if NR2F6 mRNA is Elevated or Inhibited by Company's CAR in T-Cells.

Regen BioPharma, [\(OTC-PINK: RGBP\)](#) and [\(OTC-PINK: RGBP\)](#) is a biotechnology company working in the immunology and immunotherapy space. RGBP is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is developing mRNA and small molecule therapies for treating cancer and autoimmune disorders.

RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt),

Regen BioPharma Stock Symbol: RGBP \$RGBP

Product Pipeline

Program	Indication	Milestone			
		Pre-clinical Testing	IND Submitted	IND Approved	Phase I/II
HemaXcellerate Personalized Stem Cells	Aplastic Anemia	IND #15376			
dCellVax Gene Silencing of IDO	Breast Cancer	IND #16200			
tCellVax Ex vivo siRNA NR2F6	Solid Tumors	IND #16928			
DiffronC In vivo siRNA NR2F6	MDS, Solid Tumors				
KimerApt Bispecific aptamers	Solid Tumors				
DuraCAR Gene-silenced CAR-T cells	Solid and Liquid Tumors				

Regen BioPharma Product Pipeline RGBP \$RGBP

Intellectual Property – Issued Patents

Patent Number	Patent Title	Date Granted
US-11,324,719-B2	Small molecule agonists and antagonists of NR2F6 activity in humans	2022-10-05
US-11,241,427-B2	Small molecule modulators of NR2F6 Activity	2022-02-08
US-11,141,471-B2	Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells	2021-10-12
US-11,090,332-B2	Antigen specific mRNA cellular cancer vaccines	2021-08-17
US-11,053,503-B2	Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition	2021-07-06
US-10,088,485-B2	Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand	2018-10-02
US-9,091,696-B2	Modulation of NR2F6 and methods and uses thereof	2015-07-28
US-8,389,708-B2	Method of cancer treatment using siRNA silencing	2013-03-05
US-8,263,571-B2	Gene silencing of the brother of the regulator of imprinted sites (BORIS)	2012-09-11

Regen BioPharma Patents RGBP \$RGBP

Scientific Advisory Board

Ravinder Reddy, Ph.D.
Dr. Reddy is currently a Professor of Radiology and the Director of the Center for Advanced Metabolic Imaging in Prec...
[Know more](#)

Mohammad Haris, Ph.D.
Dr. Haris is an Associate Professor in the Center for Advanced Metabolic Imaging in Precision Medicine, Department of...
[Know more](#)

Stefano Bertuzzi, PhD, MPH
Dr. Bertuzzi, is currently the Executive Director of the American Society for Cell Biology and has been named Executi...
[Know more](#)

David A. Suhay, PhD
Senior VP, Benitec Biopharma. Developed first clinical shRNA drug for hepatitis C virus.
[Know more](#)

Weiping Min, MD, PhD
Professor University of Western Ontario. First to utilize RNAi for immune modulation including cancer and organ rejec...
[Know more](#)

Amit Patel, MD, MSc
Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah.
[Know more](#)

Santosh Kesari, MD, PhD
Director of the Neuro-Oncology Program, the Neurotoxicity Treatment Center, and the Translational Neuro-Oncology Labo...
[Know more](#)

Rohit Duggal, PhD
17 years of professional experience in the drug discovery field having worked at Pfizer as a leader of the cancer site...
[Know more](#)

William S. Blaner, PhD
Professor of Nutritional Sciences at Columbia University where he studies the metabolism and actions of rethioids. He...
[Know more](#)

Regen BioPharma Scientific Advisory Board RGBP \$RGBP

modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

Confirmation Study Results Discussion of RGBP DuraCar Program and Company Finances at the Emerging Growth Conference on November 1, 2023

RGBP management presented at the Emerging Growth Conference on November 1, 2023 (<https://emerginggrowth.com/conference/>). This live, interactive online event gave existing shareholders and the investment community the opportunity to interact directly with RGBP CEO, Dr. David Koos and his team. Discussions covered recent scientific results around the company's promising DuraCAR program to treat cancers and autoimmune disorders as well as an update on current RGBP financial plans including the company's equity line.

The complete, half hour RBPB Emerging Growth Conference presentation, including audience interactive questions and answers may be seen at any time via this link:

<https://www.youtube.com/watch?v=7LhOazAjmvU>

Keynote speakers: David Koos, RGBP President / CEO & Harry M. Lander, Ph.D. Senior Scientific Consultant.

RGBP Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program; Autoimmunity to be Targeted

On October 25th RGBP released an announcement covering its previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (<https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html>). RGBP recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company's DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells which express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created.

<https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html>.

RGBP has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO which performed the initial experiments. These data confirm that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.

"Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders," says Dr. Harry Lander, Chief Scientific Consultant to RGBP. "We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6."

"Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity," says Dr. David Koos, Chairman and CEO of RGBP. "I expect that after consulting with our Board of Advisors and internally, the Company will soon have a clear picture of the specific indications and approaches it will pursue."

RGBP Receives First Phase of Confirmatory Study

CAR-T Cells Created

On October 10th RGBP issued an announcement covering its previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (<https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-experiments-validating-its-proprietary-car-t-cell-therapy-301623585.html>) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders <https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html>.

RGBP then reported it had received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent RGBP studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.

"This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA," says Dr. Harry Lander, Chief Scientific Consultant to RGBP. "We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders."

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer

to sell or offer to buy any security. CAP/FPS/CA's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated \$500 by a third party for dissemination of this article.

SOURCE: CorporateAds.com

David R. Koos, Ph.D.
Regen BioPharma Inc.
619-722-5505

[email us here](#)

Visit us on social media:

[Twitter](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/666785806>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.